Biosyent (RX) AI Stock Analysis

• Market Cap: C$135.98M
• Dividend Yield: 1.66%
• Average Volume (3M): 5.67K
• Price to Earnings (P/E): 15.5
• Beta (1Y): 0.66
• Revenue Growth: 22.22%
• EPS Growth: 25.50%
• Country: CA
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.23
• Shares Outstanding: 11,475,447
• 10 Day Avg. Volume: 6,048
• 30 Day Avg. Volume: 5,666
• PEG Ratio: 1.05
• Price to Book (P/B): 3.64
• Price to Sales (P/S): 3.64
• P/FCF Ratio: 31.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$13.50
• Price Target Upside: 13.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 78 Outperform
• Price Target: C$13.50 ▲(13.92% Upside)

Biosyent's strong financial performance and positive earnings call are the most significant factors contributing to the score. The technical analysis supports a bullish trend, although valuation metrics suggest the stock is fairly priced. Despite some product challenges and trade uncertainties, the overall outlook remains positive.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong market demand and effective sales strategies, reinforcing Biosyent's competitive position in the pharmaceutical industry.

Strong Balance Sheet

A strong balance sheet with minimal leverage enhances financial stability and provides flexibility for strategic investments and growth opportunities.

Consistent Profitability

Sustained profitability over many quarters highlights operational efficiency and a resilient business model, ensuring long-term shareholder value.

Negative Factors

Product Line Challenges

Underperformance in key product lines like Combogesic can hinder overall revenue growth and market competitiveness, requiring strategic adjustments.

Gross Profit Margin Decline

A declining gross profit margin may indicate rising costs or pricing pressures, which could impact profitability if not addressed effectively.

Trade and Tariff Uncertainties

Trade uncertainties can affect supply chains and cost structures, posing risks to international operations and profitability.

Biosyent Business Overview & Revenue Model

Company Description

Biosyent (RX) is a Canadian pharmaceutical company focused on the development, commercialization, and distribution of innovative prescription products. Operating primarily in the healthcare sector, Biosyent specializes in niche therapeutic areas, including pain management, women's health, and other specialized medical conditions. The company is committed to improving patient outcomes by providing high-quality pharmaceuticals and healthcare solutions.

How the Company Makes Money

Biosyent generates revenue primarily through the sale of its prescription products to healthcare providers, hospitals, and pharmacies. The company operates a revenue model based on direct sales and partnerships with other pharmaceutical companies for the distribution of their products. Key revenue streams include the sale of proprietary drugs, royalties from licensed products, and potential milestones from collaboration agreements. Strategic partnerships with healthcare professionals and institutions also contribute to its earnings, as they help in expanding market reach and enhancing product visibility.

Biosyent Financial Statement Overview

Summary

Biosyent demonstrates strong financial health with consistent profitability, low leverage, and improving cash flows. The company maintains a solid financial position with a low debt-to-equity ratio and strong return on equity. However, slight declines in gross profit margin and free cash flow to net income ratio suggest potential cost pressures and reinvestment needs.

Income Statement

Biosyent's income statement shows strong profitability with a consistent gross profit margin above 78% and a net profit margin around 20%. The company has demonstrated positive revenue growth, particularly in the TTM period with a 3.23% increase. EBIT and EBITDA margins are robust, indicating efficient operations. However, the slight decline in gross profit margin over the years suggests potential cost pressures.

Balance Sheet

The balance sheet reflects a solid financial position with a low debt-to-equity ratio of 0.027 in the TTM period, indicating minimal leverage. Return on equity is strong at 21.76%, showcasing effective use of equity to generate profits. The equity ratio remains stable, highlighting a well-capitalized structure. The gradual decrease in debt-to-equity over the years is a positive trend.

Cash Flow

Cash flow analysis reveals significant improvement in free cash flow growth, particularly in the TTM period with a 232.55% increase. The operating cash flow to net income ratio is healthy, indicating strong cash generation relative to profits. However, the free cash flow to net income ratio has decreased, suggesting potential reinvestment or increased capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.18M	35.03M	31.59M	27.93M	28.62M	22.33M
Gross Profit	32.67M	27.86M	25.60M	22.86M	22.64M	17.42M
EBITDA	12.72M	10.43M	9.06M	7.43M	8.64M	5.54M
Net Income	8.63M	7.27M	6.46M	5.46M	6.28M	3.80M
Balance Sheet
Total Assets	47.79M	41.36M	41.53M	40.49M	37.17M	33.57M
Cash, Cash Equivalents and Short-Term Investments	23.40M	15.94M	26.19M	28.70M	28.21M	25.58M
Total Debt	892.88K	1.04M	1.22M	1.40M	1.56M	1.71M
Total Liabilities	7.88M	6.36M	6.77M	7.12M	5.61M	6.78M
Stockholders Equity	39.90M	35.00M	34.76M	33.36M	31.55M	26.80M
Cash Flow
Free Cash Flow	7.76M	3.99M	4.88M	4.43M	4.58M	6.72M
Operating Cash Flow	8.14M	8.66M	5.05M	4.95M	4.67M	6.89M
Investing Cash Flow	2.59M	3.29M	883.85K	-10.79M	-4.84M	3.39M
Financing Cash Flow	-6.97M	-7.83M	-5.78M	-4.37M	-2.08M	-3.37M

Biosyent Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Positive. The current price of 11.85 is above the 20-day moving average (MA) of 11.61, above the 50-day MA of 11.28, and above the 200-day MA of 11.28, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 59.75 is Neutral, neither overbought nor oversold. The STOCH value of 49.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RX.

Biosyent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	78 Outperform	C$135.98M	15.46	22.35%	1.66%	22.22%	25.50%
CTX	64 Neutral	C$8.38M	18.22	2.83%	―	26.79%	―
TH	61 Neutral	―	―	―	―	5.24%	-7.99%
MDP	58 Neutral	C$84.62M	124.54	0.87%	―	2.14%	-83.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	51 Neutral	C$156.06M	-7.84	-20.49%	―	0.73%	33.51%
AQS	21 Underperform	C$663.17K	-2.04	―	―	122.30%	75.74%

Biosyent Corporate Events

BioSyent Reports Strong Financial Growth in Q3 and YTD 2025

BioSyent Inc. reported significant financial growth in Q3 and YTD 2025, with total company sales increasing by 28% and 27% respectively. The company experienced strong performance across its Canadian and international pharmaceutical sales, as well as its legacy business. Despite some gross margin compression, BioSyent maintained a consistent EBITDA margin due to proportional operating expenses. The company continues to see profitable sales growth from its FeraMAX® and Tibella®/Tibelia® products, aligning with its strategic focus on sustained growth into 2026.

BioSyent to Announce Q3 and YTD 2025 Financial Results on November 20

BioSyent Inc. has scheduled the release of its financial results for the third quarter and year-to-date 2025 on November 20, 2025, after market hours. The announcement will include a presentation by the company’s President and CEO, René Goehrum, which will be available on the company’s website. This release is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor confidence.